Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

Blood (2023) 142 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2023-184367

Published: 2023

Journal Articles

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Peter de Nully Brown, Tarec Christoffer Christoffer El-Galaly, Thomas Stauffer Larsen

Blood (2023) 142 (Supplement 1): 190.

https://doi.org/10.1182/blood-2023-182606

Published: 2023

Journal Articles

The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP

Freja Tang Severinsen, Laura Mors Haunstrup, Rasmus Kuhr Jensen, Matthew J. Maurer, Arushi Khurana, Paw Jensen, Judit M. Jørgensen, Thomas Stauffer Larsen, Michael Roost Clausen, Christian Bjørn Poulsen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Lasse H. Jakobsen

Blood (2021) 138 (Supplement 1): 53.

https://doi.org/10.1182/blood-2021-151100

Published: 2021

Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti

Blood (2021) 138 (Supplement 1): 525.

https://doi.org/10.1182/blood-2021-148359

Published: 2021

Journal Articles

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Simon Husby, Gustav Ørting Jørgensen, Francesco Favero, Jakob Schmidt Jespersen, German G.R. Gonzalez, Christian Nielsen, Betina Sørensen, Lene Hyldahl Ebbesen, John Bæch, Eva Kannik Hastrup, Pär L. Josefsson, Michael Thorsgaard, Tarec Christoffer El-Galaly, Peter de Nully Brown, Thomas Stauffer Larsen, Joachim Weisenfeldt, Kirsten Grønbæk

Blood (2021) 138 (Supplement 1): 3942.

https://doi.org/10.1182/blood-2021-145417

Published: 2021

Journal Articles

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 2978.

https://doi.org/10.1182/blood-2019-131698

Published: 2019

Journal Articles

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 5396.

https://doi.org/10.1182/blood-2019-130560

Published: 2019

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

Blood (2018) 132 (Supplement 1): 607.

https://doi.org/10.1182/blood-2018-99-109893

Published: 2018

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2018-99-112109

Published: 2018

Journal Articles

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2018-99-110602

Published: 2018

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2018-99-118690

Published: 2018

Journal Articles

Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Caroline Riley, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 5491.

https://doi.org/10.1182/blood-2018-99-117122

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 580.

https://doi.org/10.1182/blood-2018-99-111255

Published: 2018

Journal Articles

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Caroline Riley, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2018-99-117981

Published: 2018

Journal Articles

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Jorne Lionel Biccler, MSc, BSc, Kerry J Savage, BSc, MD MSc, Peter de Nully Brown, MD PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Christian Bjørn Poulsen, MD, Danny Stoltenberg, MD, Lasse H. Jakobsen, Martin Bøgsted, Professor, Diego Villa, MD, Tarec C. El-Galaly

Blood (2018) 132 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2018-99-114191

Published: 2018

Journal Articles

Higher Rates of Molecular Response to Peg-IFNa in JAK2V617F Vs. Calr Mutant MPN Patients Are Due to JAK1-Mediated STAT1 Activation and Autoregulation

Julia Czech, Sabrina Cordua, Barbora Weinbergerova, Lijuan Han, Claudia Schubert, Tim H. Brümmendorf, MD, Jiri Mayer, Prof, MD SCs, Zdenek Racil, MD, Blanka Kubesova, MSc, Trine Alma Knudsen, MD, Anders Sørensen, Morten Holmstrøm, Lasse Kjær, MSc, PhD, Vibe Skov, MSc, PhD, Thomas Stauffer Larsen, MD PhD, Hans Carl Hasselbalch, MD Professor, DMSc, Nicolas Chatain, Steffen Koschmieder

Blood (2017) 130 (Supplement 1): 4194.

https://doi.org/10.1182/blood.V130.Suppl_1.4194.4194

Published: 2017

Journal Articles

The Impact of Pre-Therapeutic Haemoglobin Levels on the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Anthracycline Containing Chemotherapy before and after the Introduction of Rituximab: A Nation-Wide Cohort Study

Michael Roost Clausen, MD, Sinna Pilgaard Ulrichsen, MSc, Thomas Stauffer Larsen, MD PhD, Bodil Himmelstrup, MD PhD, Dorthe Rønnov-Jessen, MD, Per Trøllund Pedersen, MD, Jakob Madsen, MD, Robert Schou Pedersen, MD, Pär Josefsson, MD PhD, Jette Sønderskov Gørløv, MD, Mette Nørgaard, MD PhD, Francesco d'Amore, MD PhD

Blood (2017) 130 (Supplement 1): 1566.

https://doi.org/10.1182/blood.V130.Suppl_1.1566.1566

Published: 2017

NARROW

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

A Population-Based Study on Performance of Clinical Prognostic Models in Patients with Diffuse Large B-Cell Lymphoma Younger Than 70 Years

The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms

Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Higher Rates of Molecular Response to Peg-IFNa in JAK2V617F Vs. Calr Mutant MPN Patients Are Due to JAK1-Mediated STAT1 Activation and Autoregulation

The Impact of Pre-Therapeutic Haemoglobin Levels on the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Anthracycline Containing Chemotherapy before and after the Introduction of Rituximab: A Nation-Wide Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only